A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
Status:
Completed
Trial end date:
2018-01-24
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find a recommended schedule and dose range for Emibetuzumab
when given with ramucirumab that may be safely given to participants with cancer. In Part A
of this study, escalating doses of Emibetuzumab will be given in combination with a fixed
dose of ramucirumab to evaluate the safety of the combination. After a recommended schedule
and dose range of Emibetuzumab and ramucirumab has been established, Part B of the study will
confirm safety and to see how well certain tumors respond to the combination of study drugs.
The average amount of time on study is expected to be about 6 months.